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Abstract
Infections caused by treatment-resistant non-albicans Candida species, such as C. tropicalis, has increased, which is an
emerging challenge in the management of fungal infections. Genetically related diploid sequence type (DST) strains of C.
tropicalis exhibiting reduced susceptibility to fluconazole circulated widely in Taiwan. To identify the potential source of
these wildly distributed DST strains, we investigated the possibility of the presence in soil of such C. tropicalis strains by
pulsed field gel electrophoresis (PFGE) and DST typing methods. A total of 56 C. tropicalis isolates were recovered from 26
out of 477 soil samples. Among the 18 isolates with reduced susceptibility to fluconazole, 9 belonged to DST149 and 3
belonged to DST140. Both DSTs have been recovered from our previous studies on clinical isolates from the Taiwan
Surveillance of Antimicrobial Resistance of Yeasts (TSARY) program. Furthermore, these isolates were more resistant to
agricultural azoles. We have found genetically related C. tropicalis exhibiting reduced susceptibility to fluconazole from the
human hosts and environmental samples. Therefore, to prevent patients from acquiring C. tropicalis with reduced
susceptibility to azoles, prudent use of azoles in both clinical and agricultural settings is advocated.
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Introduction
Due to the elevated number of risk populations, the prevalence
of fungal infections has increased significantly in past two decades.
Candida species are the most frequently isolated fungal pathogens
causing morbidity and mortality in seriously immunocompromised
hosts. Although Candida albicans is the most prevalent species in
hospitalized individuals and in nosocomial infections, there has
been a shift toward the more treatment-resistant non-albicans
Candida species [1,2,3,4,5]. This has become an emerging issue in
the management of fungal infection. The prevalence of these
species differed significantly in various geographic areas
[4,5,6,7,8,9,10]. Candida glabrata was the most frequently isolated
species in Western countries [4,11,12], whereas C. tropicalis
predominated in Asia [5,13,14,15]. For the treatment, azoles,
echinocandins, polyenes, and 5-flucytosine are the four major
classes of antifungal drugs. Due to low cost and less side effects,
fluconazole has become one of the most commonly prescribed
drugs.
Among the phenomena associated with azole resistance,
‘trailing’ describes the reduced but persistent growth that some
isolates exhibit at drug concentrations above the minimum
inhibitory concentrations (MICs) in broth dilution tests [16].
When the MIC of an isolate measured after 48 hours (h)
incubation is approximately 4-fold higher than that at the 24 h
point [17], the isolate is defined to have trailing growth. Thus, in
the present study, isolates with fluconazole MICs$64 mg/L or
voriconazole MICs$4 mg/L after 48 h incubation were consid-
ered to have reduced susceptibility to azole drugs.
In order to monitor the trends of species distribution and drug
susceptibilities of yeast pathogens, the Taiwan Surveillance of
Antimicrobial Resistance of Yeasts (TSARY) program was
initiated in 1999 [18]. Subsequently, two more rounds of TSARY
were conducted in 2002 and 2006. Previously, we found 23 of the
162 C. tropicalis isolates collected from TSARY in 1999 with
fluconazole MICs$64 mg/L to be closely related despite being
collected from different hospitals throughout Taiwan [19,20].
Furthermore, 5 of the 23 isolates exhibiting reduced susceptibility
to fluconazole were from hospital N4 and all belonged to the same
diploid sequence type (DST), DST140 (allele combination, 1, 3, 3,
17, 54, and 3 for ICL1, MDR1, SAPT2, SAPT4, XYR1, and
ZWF1a, respectively). However, we did not find any evidence to
suggest that these five isolates were transmitted horizontally from
person to person [21]. In addition, 2 genetically closely related
DST C. tropicalis strains, DST140 and DST98 (allele combination,
1, 3, 3, 17, 9, and 3), exhibited reduced susceptibility to
fluconazole were identified in TSARY 1999 and 2006. Among
them, 18 DST140 isolates were recovered from 10 different
hospitals located in all 4 geographic regions in Taiwan and 7
DST98 ones were recovered from 4 different hospitals, two each in
northern and southern Taiwan. There were also 3 DST149 (allele
combination, 1, 44, 3, 7, 58, and 3) isolates exhibiting reduced
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northern Taiwan were identified. These results indicated that
those DST strains exhibiting reduced susceptibility to fluconazole
circulated widely in Taiwan from 1999 to 2006 and their presence
was not a result of outbreaks in certain hospitals or geographic
regions [21].
Exposure to azole compounds paves the way for the selection
and enrichment of fungal isolates exhibiting reduced susceptibility
to drugs, which may occur in patients receiving azole treatments.
However, emergence of person to person transmission of isolates
exhibiting reduced susceptibility to fluconazole during medical
treatment is unlikely. Alternatively, the use of azole compounds in
the environment may select organisms exhibiting reduced
susceptibility to drugs, which may find their ways to human.
Candida tropicalis is prevalent in organically enriched soil and
aquatic environments [22] as well as in wild birds [23]. Thus, in
the present study, we investigated the presence in soil of these C.
tropicalis strains exhibiting reduced susceptibility to fluconazole,
especially DST98, DST140, and DST149.
Results
Candida tropicalis isolates
A total of 56 C. tropicalis isolates (Table 1) analyzed in the present
study were recovered from 26 of the 477 soil samples collected from
2006 to 2008 around Taiwan. The positive culture rates of C.
tropicalisfrom varioustypes ofsoil differed significantly.Itwas85.7%
(6/7) for petroleum-contaminated soil samplings, 44.8% (13/29) for
agricultural fields, 38.5% (5/13) for sludge soil, and 0.5% (2/427)
for forest soil. To identify whether multiple strains were present in a
sample, three individual colonies (if present) of each representative
morphotype in every soil sample were picked for subsequent
workup. In the present study, 10 samples had only one C. tropicalis
isolate recovered, 8 had 2, 5 had 3, 2 had 4, and 1 had 7(Table 1).
All isolates were susceptible to amphotericin B. Among the 18
isolates with fluconazole MICs$64 mg/L after 48 h incubation, 17
had voriconazole MICs$4 mg/L as well. Nevertheless, they all
exhibited trailing growth phenotype.
Molecular typing
To determine whether the C. tropicalis isolates with reduced
susceptibility to fluconazole recovered from soil samples were
genetically related to those from human, we applied pulsed field
gel electrophoresis (PFGE) method to analyze their genetic
relatedness. The 18 isolates that were investigated included 11
soil and 7 human isolates. The soil isolates comprised 6 isolates
exhibiting reduced susceptibility to fluconazole (NHUE10, 28, 33,
40, 48, and 56) and 5 susceptible ones (NHUE11, 27, 36, 42, and
52). The 7 clinical isolates (YM990275, 490, 537, 579, 592, 649,
and 659) all exhibited reduced susceptibility to fluconazole. As
expected, all 6 DST140 isolates from human shared an
indistinguishable PFGE pattern (Fig. 1). In addition, 2 isolates
exhibiting reduced susceptibility to fluconazole from soil,
NHUE48 and NHUE56, shared the same PFGE pattern with
those human isolates. Among the remaining 4 soil isolates
exhibiting reduced susceptibility to fluconazole, 3 (NHUE28,
NHUE33, NHUE40), from different samples, shared at least 97%
similarity. Furthermore, fluconazole susceptible isolates recovered
from soil were not closely related to the ones exhibiting reduced
susceptibility to fluconazole from the same areas, i.e. NHUE 11 vs.
NHUE 10, NHUE 36 vs. NHUE 33, and NHUE 42 vs. NHUE
40. The fact that YM990579, a DST149 human isolate, also
shared the indistinguishable PFGE pattern with the six DST140
human isolates, suggests that MLST has a higher discriminatory
Table 1. Characteristics of Candida tropicalis isolates from
soils (N=56).
minimum inhibitory concentration (mg/L)
Isolate Sample DST Amp 48 h Flu 24 h Flu 48 h Vor 48 h
NHUE1 16 ND 0.5 0.25 0.5 0.0313
NHUE2 16 ND 0.5 0.25 0.5 0.0313
NHUE3 17 ND 0.5 0.25 0.5 0.0313
NHUE4 17 ND 0.5 0.25 0.5 0.0313
NHUE5 17 ND 0.25 0.25 0.5 0.0313
NHUE6 18 ND 0.5 0.25 0.5 0.0625
NHUE7 18 ND 0.5 0.25 0.5 0.0313
NHUE8 18 ND 0.5 0.25 0.5 0.0625
NHUE9 19 ND 1 0.25 0.5 0.0625
NHUE10 20 140 0.5 0.25 .64 .8
NHUE11 20 231 0.5 0.25 0.5 0.0313
NHUE12 21 ND 0.5 0.25 0.5 0.0313
NHUE13 21 ND 0.5 0.25 0.5 0.0313
NHUE14 21 ND 0.5 0.25 0.5 0.0313
NHUE15 26 ND 0.5 0.25 0.5 0.0313
NHUE16 27 ND 1 0.25 0.5 0.0625
NHUE17 28 149 0.5 0.5 .64 .8
NHUE18 28 149 0.5 0.5 .64 .8
NHUE19 28 149 0.5 0.5 .64 .8
NHUE20 7 ND 0.5 0.25 0.5 0.0625
NHUE21 4 226 0.5 0.25 64 0.0313
NHUE22 4 226 0.5 0.25 8 8
NHUE23 5 168 0.5 0.5 .64 .8
NHUE24 5 ND 0.5 0.25 0.5 0.0156
NHUE25 5 ND 1 2 4 0.0625
NHUE26 5 ND 0.5 2 2 0.0625
NHUE27 23 229 0.5 0.5 1 2
NHUE28 24 149 0.5 0.5 .64 .8
NHUE29 24 149 0.5 4 .64 .8
NHUE30 24 149 0.5 0.5 .64 .8
NHUE31 24 ND 0.5 0.25 0.5 0.0313
NHUE32 22 ND 0.5 0.125 1 0.25
NHUE33 22 149 0.5 2 .64 .8
NHUE34 22 149 0.5 0.125 .64 .8
NHUE35 25 ND 0.0313 0.125 0.125 ND
NHUE36 25 230 0.5 0.25 0.25 0.0156
NHUE37 6 183 0.5 0.5 .64 4
NHUE38 6 ND 0.0313 0.25 0.25 1
NHUE39 6 187 0.5 0.5 .64 .8
NHUE40 6 149 0.5 0.5 .64 .8
NHUE41 6 227 1 0.5 .64 .8
NHUE42 6 139 0.5 0.125 0.5 0.125
NHUE43 6 227 0.5 1 .64 .8
NHUE44 8 ND 0.5 0.25 0.5 0.0625
NHUE45 8 ND 0.5 0.25 0.5 0.0625
NHUE46 9 ND 0.5 0.25 0.5 0.0313
NHUE47 11 ND 0.5 0.25 0.5 0.0313
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further employed MLST to compare the genetic relatedness
among all 18 soil isolates exhibiting reduced susceptibility to
fluconazole. Among them, 9 from 4 soil samples (#6, 22, 24, and
28) were DST149 and 3 from 2 soil samples (#3 and 20) were
DST140 (Table 1). In addition to DST140 and DST149, 10
additional DST patterns were identified from 13 isolates in the
present study. They were DST139 (allele combination, 1, 4, 22,
23, 36, and 9), DST168 (allele combination, 1, 3, 3, 17, 57, and 3),
DST183 (allele combination, 1, 20, 12, 17, 68, and 3), DST187
(allele combination, 1, 63, 2, 30, 69, and 25), DST191 (allele
combination, 9, 54, 2, 10, 70, and 9), DST226 (allele combination,
1, 80, 27, 10, 44, and 9), DST227 (allele combination, 5, 54, 1, 47,
48, and 22), DST229 (allele combination, 1, 82, 3, 17, 57, and 3),
DST230 (allele combination, 1, 4, 12, 10, 3, and 9), and DST231
(allele combination, 27, 9, 1, 43, 23, and 7). DST140 and DT168
are closely related. They are single locus variants and differ by only
one SNP (nt 242) in the XYR1 gene. Among the 6 tested
fluconazole susceptible isolates, NHUE22 (MIC=8 mg/L) was
less susceptible than the other 5 (MIC , – – 1 mg/L) and they all had
their own unique DST. Interestingly, NHUE22 and NHUE21
were both from sample 4 and belonged to DST226.
Growth curves
All 18 soil isolates with fluconazole MICs$64 mg/L after 48 h
incubation, such as NHUE40, NHUE48, YM9900579, and
YM990649, were able to grow in the presence of 64 mg/L
fluconazole (Fig. 2). In contrast, the growth of the susceptible ones
Table 1. Cont.
minimum inhibitory concentration (mg/L)
Isolate Sample DST Amp 48 h Flu 24 h Flu 48 h Vor 48 h
NHUE48 13 140 0.5 0.5 .64 .8
NHUE49 13 ND 1 0.125 0.25 0.0156
NHUE50 14 227 0.5 0.5 1 .8
NHUE51 15 ND 1 0.25 0.5 0.0625
NHUE52 15 191 0.25 0.25 1 0.5
NHUE53 12 ND 0.5 0.25 1 0.125
NHUE54 12 ND 0.5 0.25 0.5 0.0313
NHUE55 10 ND 0.5 0.25 0.5 0.0313
NHUE56 3 140 0.5 0.25 .64 4
ATCC 6258 ND 1 8 32 0.25
ATCC 90028 ND 0.5 1 2 0.0313
ATCC 22019 ND 0.5 0.125 0.125 0.0156
ATCC13803 ND ND 0.5 0.5 ND
DST, diploid sequence type; h, hours; ND, not determined; amp, amphotericin B;
flu, fluconazole; vor, voriconazole;
doi:10.1371/journal.pone.0034609.t001
Figure 1. Dendrogram of 18 Candida tropicalis isolates from human and soil. The Dice coefficient was used to analyze the similarities
between the PFGE band patterns. UPGMA was used for the cluster analysis. The position tolerance and optimization were set at 1%. A total of 7
isolates were recovered from human (YMs) and 11 from soil (NHUEs). MIC refers to fluconazole MIC (in mg/L). An MIC of 64 indicates isolates with
reduced susceptibility.
doi:10.1371/journal.pone.0034609.g001
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ATCC13803 (Fig. 2, crosses solid line). Hence, those isolates with
fluconazole MICs$64 mg/L definitely had reduced susceptibility
to fluconazole than those isolates with lower fluconazole MICs.
Susceptibilities to drugs used in agriculture
Since 17 of the 18 soil isolates exhibiting reduced susceptibility
to fluconazole also had high voriconazole MICs, we selected 6
isolates to investigate whether isolates with reduced susceptibility
to fluconazole from human and soil also had reduced susceptibility
to other azole drugs used in agriculture. The relative growth of 6
isolates after incubation for 48 h is showed in Table 2. In the
presence of 64 mg/L fluconazole, isolates exhibiting fluconazole
reduced susceptibility, NHEU40, NHUE48, YM990579, and
YM990649 grew better (66–100% of growth) than the fluconazole
susceptible ones, ATCC13803 and NHUE42 (27–32% of growth),
confirming our previous results obtained from broth microdilution
method. All tested isolates grew poorly (10–11% of growth) in the
presence of 64 mg/L penconazole and tebuconazole. Interesting-
ly, the 4 isolates exhibiting fluconazole reduced susceptibility grew
better than fluconazole susceptible ones in the presence of 4 mg/L
penconazole (36–60% vs. 23–24% of growth), 4 mg/L tebucona-
zole (54–83% vs. 12–15% growth), 16 mg/L fluquinconazole (71–
87% vs. 41–59% of growth), or 64 mg/L tridimenol (24–35% vs.
15–17% growth). Hence, isolates exhibiting fluconazole reduced
susceptibility were also less susceptible than the fluconazole
susceptible ones to other azole drugs used in agriculture.
Discussion
Candida tropicalis is one of the most frequently isolated non-
albicans Candida species from patients [8,10,24,25]. Furthermore,
C. tropicalis develops drug resistance in the presence of fluconazole
much more rapidly than other Candida species [26,27]. Our
findings in the present study suggest that soil may be a potential
source of C. tropicalis with reduced susceptibility to azole type of
antifungal drugs.
The observation that 3 C. tropicalis isolates (NHUE28-30) with
reduced susceptibility to fluconazole recovered from the same soil
sample, #24, belonged to the same DST strain (DST149) suggests
that they may be the progenies of the same strain. Nevertheless,
one isolate (NHUE31) recovered from the same #24 soil sample
was susceptible to fluconazole. On the other hand, of the 7 isolates
(NHUE37-43) recovered from another soil sample, #6, 5
exhibited reduced susceptibility to fluconazole and belonged to 4
different DSTs (DST183, 187, 149, and 227). These results
indicated that multiple strains of C. tropicalis exist in a single soil
sample.
Long duration of drug exposure and high numbers of
reproducing microorganisms contribute to the selection and/or
enrichment of drug-resistant individuals. In fungi, drug resistance
is more likely to be the outcome of sequential accumulation of
adaptive mutations in the chromosomes [28,29]. Azole-resistant
isolates have been shown to emerge following microbial exposure
to the drugs in patients and in agricultural settings. The
observation that azole-resistant Aspergillus fumigatus isolates recov-
ered from soil and compost were genetically related to clinical
resistant isolates suggests the existence of an environmental route
for developing drug resistance in fungi [30,31,32]. Similar to some
antibiotic resistance in bacteria [33,34,35], fluconazole resistance
in fungi also involves step-wise mutations affecting more than one
Figure 2. Growth curves of different C. tropicalis isolates with
different fluconazole susceptibilities. Six isolates, ATCC13803
(rectangles), NHUE40 (diamonds), NHUE42 (triangles), NHUE48 (circles),
YM990579 (crosses), and YM990649 (stars) were grown in the RPMI
medium 1640 (Gibco BRL31800-022) in the absence (dot lines) or in the
presence of 64 mg/L (solid lines) fluconazole.
doi:10.1371/journal.pone.0034609.g002
Table 2. Relative growth of six C. tropicalis strains in the presence of different drugs.
Drug none Fluconazole Penconazole Tebuconazole Tridimenol Fluquinconazole
Concentration (mg/L) 4 64 4 64 4 64 4 64 4 16*
ATCC13803 100
# 34
1 27 23 11 15 10 49 15 55 41
NHUE40 100 71 71 36 10 58 10 71 34 68 77
NHUE42 100 30 32 24 11 12 10 60 17 75 59
NHUE48 100 87 100 54 11 83 11 78 35 94 87
Ym990579 100 71 66 40 10 59 10 75 35 83 72
Ym990649 100 92 81 60 11 54 11 65 24 100 87
*Due to the solubility of fluquinconazole, the highest concentration of this drug in the present study was 16 mg/L instead of 64 mg/L.
#The growth of each isolate in the absence of drug was defined as 100% and the relative growth of each isolate in the presence of drugs was normalized accordingly.
1Drugs capable of reducing the growth of cells by more than 50% are in bold, considered as susceptible to the concentrations of drugs.
doi:10.1371/journal.pone.0034609.t002
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exhibiting trailing growth phenomena in the present study are
prone to be resistant.
In the present study, we have found that C. tropicalis isolates with
fluconazole MICs$64 mg/L recovered from human and from
soil, albeit from different geographic regions of Taiwan, shared
indistinguishable PFGE patterns and belonged to the same DSTs.
Whether the original development of C. tropicalis exhibiting
reduced susceptibility to fluconazole occurred in human hosts or
in the environments needs further investigation. However, our
observation is consistent with the idea that medically important
drug resistant isolates, not only bacteria but also fungi, exist in the
environments.
Previous study has shown that in human immunodeficiency
virus infected patients, C. albicans and other yeast species were
cross-resistant to medical and agricultural azole drugs [39].
However, no C. tropicalis was recovered in that study. The
observation that isolates with reduced fluconazole susceptibility
were also more resistant than the susceptible ones to fluquinco-
nazole and tridimenol but not to penconazole and tebuconazole
(Table 2) may explain why the later two but not the former two are
still used in agriculture in Taiwan. According to the data of
‘‘Domestic Manufacturers Production & Sale of Pesticides ‘‘
published by the Taiwan Crop Protection Industry Association,
there is an increased amount of azole-type compounds used in the
agriculture in Taiwan, from approximately 100 tons in 2005 to
145 tons in 2009 (about 45% increase). Since both efficient
reproduction and spreading of resistant fungi in the environment
are to be anticipated, we are confronted with the major challenge
of drug-resistance development in environmental setting on a
global scale. Hence, to reduce and prevent patients from acquiring
azole-resistant C. tropicalis and other fungal species, it is advisable
to take precaution against unnecessary use of azoles in not only
clinical but also agricultural settings. The mechanisms contribut-
ing to the reduced susceptibility to azole drugs are under
investigation. Further study should be performed to compare C.
tropicalis isolates recovered from soils in the fields as well as those
from farmers for genetic relatedness and susceptibility to various
antifungal drugs.
Materials and Methods
Strain isolation
To isolate yeasts from the soil, we transferred approximately
one gram of soil from each sample into a tube containing nine ml
of sterile water and vortex-mixed. Diluted 0.2 ml of suspensions
were plated onto acidified YMA (1% glucose, 0.5% peptone, 0.3%
yeast extract, 0.3% malt extract, 1.5% agar, pH3.5) or Dichloran
Rose Bengal Chloramphenicol agar (Merck, Darmstadt, Ger-
many). After incubation at 24uC for 3 days, three (if present)
representative colonies of each morphotype were picked for
subsequent workup. All yeast isolates were identified by the
sequences of the D1/D2 domain of the LSU rRNA genes as
described by Lee et al. [40].
Drug susceptibility testing
The MICs of amphotericin B (0.0313–16 mg/L), fluconazole
(0.125–64 mg/L), and voriconazole (0.0156–8 mg/L) were deter-
mined by the same in vitro antifungal susceptibility testing
established in our laboratory [41,42] according to the guidelines
of M27-A3 recommended by the Clinical and Laboratory
Standards Institute [43]. RPMI medium 1640 (31800-022, Gibco
BRL) was used for the dilution and growth of the yeast culture.
Strains from American Type Culture Collection (ATCC),
including C. albicans (ATCC 90028), C. krusei (ATCC 6258), and
C. parapsilosis (ATCC 22019), were used as the standard controls.
Growth of each isolate was measured by the Biotrak II plate
spectrophotometric reader (Amersham Biosciences, Biochrom
Ltd., Cambridge England) after incubation at 35uC for 24 h and
48 h.
The MIC of amphotericin B was defined as the minimum
inhibitory concentrations of the drug capable of inhibiting cell
growth. For susceptibility to amphotericin B, isolates with
MIC§2 mg/L were considered to be resistant and those with
MIC, – –1 mg/L were susceptible. The MIC for fluconazole and
voriconazole was defined as the lowest concentration capable of
reducing the turbidity of cells by more than 50%. Isolates with
fluconazole MICs$64 mg/L were considered as to have reduced
susceptibility and #8 mg/L susceptible. The isolates with MICs
in the range of 16–32 mg/L were referred to as susceptible-dose
dependent (SDD). Isolates with voriconazole MICs$4 mg/L
were considered as with reduced susceptibility and #1 mg/L
susceptible. The isolates with MIC 2 mg/L were referred to as
SDD.
Pulsed field gel electrophoresis (PFGE)
A total of 18 isolates were examined by PFGE, including 11 soil
and 7 human isolates. The soil isolates comprised 6 (NHUE10, 28,
33, 40, 48, and 56) exhibiting fluconazole reduced susceptibility
and 5 best matched susceptible ones isolated either from the same
sample or from the same type of soil in the same area, NHUE11,
27, 36, 42, and 52 (vs. NHUE10, 28, 33, 40, and 48, respectively).
The 7 human isolates, YM990275, 490, 537, 579, 592, 649, and
659, all exhibited reduced susceptibility to fluconazole. Pulsed field
gel electrophoresis (PFGE) was performed based on our previous
report [44] with some modifications. Briefly, organisms were
grown on sabouraud dextrose agar (SDA) plate at 30uC overnight,
after which the organisms were embedded in 1% agarose gel
(SeaKem Gold agarose, FMC BioProducts). The plugs were
subjected to cell lysis by lyticase at 37uC for 2 h, and then treated
with proteinase K in 50 mM EDTA buffer at 50uC for 16 h. The
genomic DNA was digested with 4 units of BssHII at 37uC for
16 h. Electrophoresis was then performed with a CHEF MAPPER
system (Bio-Rad, Hercules, Calif., USA) in 0.56TBE buffer at
6 V/cm at 14uC with alternating pulses at an angle of 120 degrees
in a 5–50 s pulse-time gradient for 20 h. A ladder of Salmonella
choleraesuis subsp. choleraesuis (Smith) Weldin serotype Braenderup
(ATCC BAA664) was used as the molecular weight marker. The
PFGE pattern was analyzed by BioNumerics software (Version
4.5, Applied Maths, Kortrijk, Belgium). The position tolerance
was set at 1% and optimization was set at 1%. The Dice coefficient
was used to analyze the similarities of the band patterns. The
unweighted pair group method using arithmetic averages
(UPGMA) was used for cluster analysis.
Multilocus sequence typing
A total of 18 isolates exhibiting reduced susceptibility to
fluconazole and 5 best matched susceptible ones (either from the
same sample or from the same type of soil in the same area),
NHUE11, 27, 36, 42, and 52 (vs. NHUE10, 28, 33, 40, and 48,
respectively) as well as NHUE 22 with MIC of fluconazole 8 mg/L,
were analyzed. Based on our previous report [19], the DNA
fragments of six genes: ICL1, MDR1, SAPT2, SAPT4, XYR1,a n d
ZWF1a were sequenced for the analyses. The resulted sequences
were aligned with BioNumerics 3.0 (Applied Maths, Kortrijk,
Belgium) and compared with those in the database of C. tropicalis
(http://pubmlst.org/website) to obtain the identifiers (DST).
C. tropicalis from Human and Soil
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The Bioscreen C analyzer (Oy Growth Curves AB Ltd,
Helsinki, Finland) was used to re-assess the growth of different
isolates. Approximately 1610
4 cells in 200 ml of RPMI medium
1640 (Gibco BRL31800-022) were grown in the absence or in the
presence of different drugs, including fluconazole, fluquincona-
zole, penconazole, tebuconazole, and tridimenol, at 35uC.
According to the record from the Taiwan Corp Protection
Industry Association, penconazole and tebuconazole but not
fluquinconazole and tridimenol were currently in use for
agriculture in Taiwan. The growths of cells were determined
every 15 minutes. Due to the solubility of fluquinconazole, the
highest concentration of this drug in the present study was 16 mg/L
instead of 64 mg/L. The experiments were repeated twice with
similar results.
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